Abzena
PrivateLast Round
Private Equity
Mar 31, 2022
Est. Valuation
$44.4M
Total Funding Raised
$126.9M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Abzena operates in Healthcare & Life Sciences and is based in Raleigh, North Carolina. Its latest recorded funding round was a Private Equity round in March 2022.
Abzena is a biotechnology company that provides integrated discovery, development, and manufacturing services for biologics and antibody-drug conjugates (ADCs).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine, Pharma Supply Chain
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Abzena Comparables
Compare Abzena with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MabPlex | 88% | |
| JSR Life Sciences | 80% | |
| Enzene Biosciences | 80% |
For institutional investors. Book with your work email.
Abzena Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Equity | Mar 31, 2022 | ||||
| Growth Equity | Jul 28, 2020 | ||||
| Take Private | Aug 17, 2018 | ||||
| Follow-on Offering | Apr 5, 2017 | ||||
| Private Placement | Nov 24, 2015 | ||||
IPO | Jul 10, 2014 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Abzena Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Invesco Ltd. | Follow-on Offering |
| Biospring Partners | Private Equity, Growth Equity |
| Cavendish | IPO |
| Woodford Investment Management | IPO, Follow-on Offering |
| Imperial Innovations | IPO, Follow-on Offering, Series A |
| Invesco Perpetual | Series A, IPO |
| Welsh, Carson, Anderson & Stowe | Private Equity, Take Private |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 1, 2026
Open roles increased to 852, 2.5x the trailing average.
- Jul 13, 2026
Open roles increased to 146, 33% of headcount.
For institutional investors. Book with your work email.
Abzena Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Abzena's valuation, stock price, and market status.
Is Abzena a public or private company?
Abzena is a private company.
What is the current stock price of Abzena?
Abzena is a private company, so its shares have no public market price. Caplight tracks Abzena's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Abzena worth (valuation)?
Abzena's valuation is estimated at $44.4M based on funding round data.
Can I buy Abzena stock?
Abzena shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Abzena's last funding round?
Abzena's most recent funding round was Private Equity on March 31, 2022.
Who are the main investors in Abzena?
Key investors in Abzena include Biospring Partners, Cavendish, Imperial Innovations, Welsh, Carson, Anderson & Stowe.
Will Abzena IPO soon?
No public IPO plans have been announced for Abzena.
How can I track Abzena secondary market activity?
Caplight tracks bids, offers, and trades in Abzena's shares on secondary markets.